Home intravenous anti-infective therapy (HIVAT) has become an accepted mode of treatment worldwide.
There are a number of risks intrinsic to such therapy which can be reduced by a team approach, coupled with careful patient selection criteria, a structured follow-up process and an emphasis on patient education.
The benefits of HIVAT include the well-being accrued as a result of being at home, the possibility of returning to work or school, and a reduced risk of infectious and intravenous (IV) cannula-related problems.
From a societal standpoint, economic cost-benefit analyses provide ample evidence of cost effectiveness.
Studies indicate that potential risks, such as noncompliance, interruption of therapy, drug and IV catheter-associated problems, are infrequent.
In the US, reimbursement for HIVAT services for the elderly remains a problem.
Mots-clés Pascal : Antibactérien, Antibiotique, Antiviral, Antifongique, Voie intraveineuse, A domicile, Autoadministration, Homme, Evaluation, Analyse avantage coût, Economie santé
Mots-clés Pascal anglais : Antibacterial agent, Antibiotic, Antiviral, Antifungal agent, Intravenous administration, At home, Self administration, Human, Evaluation, Cost benefit analysis, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0057732
Code Inist : 002B02S07. Création : 199608.